HHLR Advisors’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

HHLR Advisors’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-944,716	Closed	-$26.1M	–	97
2021 Q1	$26.1M	Sell	944,716 -102,971	-10%	-$3.08M	0.26%	42
2020 Q4	$35.6M	Buy	1,047,687 +697,687	+199%	+$21.2M	0.28%	44
2020 Q3	$8.4M	Hold	350,000	–	–	0.06%	69
2020 Q2	$8.15M	Buy	+350,000	New	+$6.93M	0.07%	57

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HHLR Advisors's CALT Position: Q2 2021 in Review

HHLR Advisors sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2021, closing a stake of 944,716 shares — an estimated $26.1M sold.

HHLR Advisors first reported a position in CALT in Q2 2020 and held it in 4 quarters. The position peaked at $35.6M in Q4 2020. 14 funds tracked by Wall St. Rank hold CALT as of Q2 2021.

HHLR Advisors reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2021 after selling out during the quarter.
HHLR Advisors sold 944,716 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2021, an estimated $26.1M.
HHLR Advisors first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 4 quarters.
HHLR Advisors's Calliditas Therapeutics AB American Depositary Shares position peaked at $35.6M in Q4 2020.
14 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2021.

Based on HHLR Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.